2025 marked a year of consolidation and momentum in gastroenterology, shaped less by single breakthroughs and more by how rapidly new evidence translated into practice. From a wave of FDA approvals in IBD to evolving guidelines that pushed earlier use of high-efficacy therapies, the field sharpened its focus on durability, flexibility, and patient-centered care. Progress also extended beyond IBD, with advances in pediatric IBS-C, gastroparesis, and colorectal cancer prevention. How these developments collectively reset clinical priorities is explored in this year-in-review from HCPLive.
Keep Reading
Add A Comment